MedTrace Logo

Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment

NCT02891681 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2021-02-16

Study results available
· View outcomes & findings →

Summary

To determine the accuracy of NIR/US assessment of tumor vasculature and oxygen changes in predicting and monitoring early neoadjuvant treatment response compared to pathological response.

Conditions

  • Breast Cancer
  • Breast Tumors
  • Cancer of Breast
  • Cancer of the Breast
  • Malignant Neoplasm of Breast

Interventions

DEVICE

Optical Tomography Using Near Infrared Diffused Light Assisted with Ultrasound

Sponsors & Collaborators

  • National Institute for Biomedical Imaging and Bioengineering (NIBIB)

    collaborator NIH

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Quing Zhu, Ph.D. · Washington University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-29
Primary Completion
2020-01-23
Completion
2020-01-23
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02891681 on ClinicalTrials.gov